And this may lead to an FDA approval for us in the future. There are ongoing studies also to explore the right dose of T-DXd. So, I think really understanding some of the toxicities is key. Overall, well tolerated, but the main reason for treatment discontinuation in this agent has been pneumonitis. There are some toxicities associated with this agent. And overall, really promising progression-free survival, as well as overall survival. They demonstrated a response rate of about 50%. And in their initial cohort of patients, it really showed that there is significant activity of this agent in patients with advanced non–small cell lung cancer with HER2 mutations.
#Emory news center trial
We have results from the DESTINY-Lung01 trial that looked at T-DXd in patients with HER2 mutations advanced non–small cell lung cancer. We see HER2 mutations in about 1% to 2% of patients with nonsquamous non–small cell lung cancer. We know that HER2 mutations identified on NGS, it's an actionable mutation, at least so far, in the studies that have been done. It's actually a very exciting area of active investigation for patients with advanced non–small cell lung cancer. Is this an area of exploration in HER2 lung cancer, as well?
Results from DESTINY-Lung01 have shown promising progression-free survival and overall survival with ongoing research that may lead to a future FDA approval, said Ticiana Leal, MD, associate professor, director of the Thoracic Medical Oncology Program, Department of Hematology and Medical Oncology, Emory University School of Medicine.Īt ASCO this year, there were critical findings about treatment of HER2-low breast cancer with trastuzumab deruxtecan. political landscape that spurred new levels of corporate activism not to mention a growing divide in what people want from institutions and companies.
0 kommentar(er)
